Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bayerische Motoren Werke ADR (BMWYY)

Bayerische Motoren Werke ADR (BMWYY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Soligenix (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat

A recent “Times of India” report spotlighted the danger posed by ricin, a highly toxic plant-derived compound with no known antidote and a history of attempted misuse by extremist actors. Soligenix...

SNGX : 1.3700 (-4.86%)
BMWYY : 29.2000 (+4.58%)
Nutriband (NASDAQ: NTRB) Signs LOI to Explore Quantum-AI Technology Collaboration

Nutriband (NASDAQ: NTRB) announced the signing of a nonbinding letter of intent with the Qvanta Group of Companies to explore potential collaboration involving secure artificial intelligence, advanced...

NTRB : 4.80 (+1.27%)
BMWYY : 29.2000 (+4.58%)
Soligenix (NASDAQ: SNGX) Receives Strong Vote of Confidence from Zacks Report Despite Muted Market Response to Clinical Milestone

When a late-stage clinical trial reports response rates nearly double what researchers expected, yet the stock market barely reacts, seasoned analysts take notice and wonder if investors are missing something...

SNGX : 1.3700 (-4.86%)
BMWYY : 29.2000 (+4.58%)
Soligenix (NASDAQ: SNGX) Reaches Key Enrollment Milestone in Phase 3 Trial with Encouraging Blinded Response Rate

In a pivotal advancement for patients suffering from a rare form of skin cancer, Soligenix (NASDAQ: SNGX) has achieved a critical clinical trial milestone that brings its investigational treatment significantly...

SNGX : 1.3700 (-4.86%)
BMWYY : 29.2000 (+4.58%)
Soligenix (NASDAQ: SNGX) Elevates Advisory Network as Rare Disease Strategy Advance

Soligenix (NASDAQ: SNGX) is entering a new phase of strategic breadth and influence with the appointment of a seasoned, high-level scientific and policy adviser who brings rarefied experience at the intersection...

SNGX : 1.3700 (-4.86%)
BMWYY : 29.2000 (+4.58%)
Soligenix (NASDAQ: SNGX) Strengthens CTCL Program as DMC Flags No Safety Issues

In a key development that underscores the advancing clinical trajectory of its lead therapy, Soligenix (NASDAQ: SNGX) announced that the Data Monitoring Committee (“DMC”) overseeing its confirmatory...

SNGX : 1.3700 (-4.86%)
BMWYY : 29.2000 (+4.58%)
CNS Pharmaceuticals (NASDAQ: CNSP) Targets Glioblastoma with Innovative Therapies, Addressing One of Oncology’s Greatest Unmet Needs

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in novel treatments for primary and metastatic brain cancers is sharpening its focus on glioblastoma multiforme (“GBM”),...

CNSP : 6.17 (-0.48%)
BMWYY : 29.2000 (+4.58%)
Soligenix (NASDAQ: SNGX) Strengthens Financial Foundation to Advance Multiple Value Drivers

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and biodefense programs, continues to fortify its financial position as it advances toward a series of pivotal...

SNGX : 1.3700 (-4.86%)
BMWYY : 29.2000 (+4.58%)
Soligenix (NASDAQ: SNGX) Strengthens Advisory Leadership in Cutaneous T-Cell Lymphoma

Soligenix (NASDAQ: SNGX), a clinical-stage biotechnology company focused on rare diseases and public health solutions, has rejuvenated its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (“CTCL”),...

SNGX : 1.3700 (-4.86%)
BMWYY : 29.2000 (+4.58%)
Nutriband (NASDAQ: NTRB) Receives FDA Meeting Feedback Advancing AVERSA(TM) Fentanyl Toward 505(b)(2) NDA Submission

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, today announced it has received final meeting minutes from its Sept. 18, 2025, virtual meeting with the U.S. Food...

NTRB : 4.80 (+1.27%)
BMWYY : 29.2000 (+4.58%)

Barchart Exclusives

The Saturday Spread: Using Risk Topography to Plan Your Options Strategies (JD, NTAP, ZS)
While derivatives offer significant upside potential, trading these contracts requires precision. Here’s how to get a leg up, even against Wall Street pros. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar